Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hodgen, G. D.
Right arrow Articles by Chwalisz, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hodgen, G. D.
Right arrow Articles by Chwalisz, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 9, No. suppl_1, pp. 77-81, 1994
© 1994 European Society of Human Reproduction and Embryology

Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models

Gary D. Hodgen1, J.F.H.M. van Uem2, Claudio F. Chillik3, Douglas R. Danforth4, Jean Philippe Wolf5, Joseph Neulen6, Robert F. Williams1 and Kris Chwalisz7

1 The Jones Institute for Reproductive Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School 601 Colley Avenue, Norfolk, VA 23507, USA 2 Nurnberger Strasse 35 91052 Erlangen, Germany 3 Centro de Estudios Ginecologicos y Reproducion Buenos Aires, Argentina 4 The Ohio State University, Department of Obstetrics and Gynecology Means Hall, Room 551, 1654 Upham Drive, Columbus, OH 43210-1228, USA 5 Assistance Publique, Hospitaux de Paris, Laboratorie D'Histologie-Embryologie, Centre Hospitalier 78 rue de General LeClerc, 94270 Kremlin-Bicetre, France 6 Department Klinische Endokrinologie, Universitaets-Frauenklinik 79106 Freiburg, Germany 7 Research Laboratory of Schering Aktiengesellschaft, Fertility Control and Hormone Therapy Research D-13342 Berlin, Germany

We have summarized some of the studies containing basic biological data suggesting potential therapeutic utility of the anti-proliferative activity of antiprogestins on uterine tissues. The non-competitive anti-oestrogenic effects of RU486 were examined using oestradiol treated ovariectomized monkeys given RU486, progesterone or both. The oestradiol-induced luteinizing hormone surge of control animals was abrogated by progesterone and/or RU486. Secretory transformation by progesterone was inhibited by RU486 co-administration. RU486 alone (1 mg/kg) induced endometrial secretory transformation, but higher doses (5 mg/kg) induced inhibited proliferation and secretory activity. Thus, in the presence of progesterone, RU486 is antagonistic but, in its absence, RU486 exhibits endometrial progestational effects at low doses and an anti-proliferative (anti-oestrogenic) effect at higher doses. These data encourage continued evaluation of RU486 as a potential contraceptive agent acting at the pituitary and/or endometrial level. Our study also demonstrates that after physiological oestradiol replacement therapy, oestradiol receptor concentrations rise dramatically following antiprogestin treatment; this effect was dose-dependent.

Key words: antagonist/anti-oestrogen/antiprogestin/endometrium/proliferation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.